Information Provided By: 
Fly News Breaks for July 26, 2016
PTCT
Jul 26, 2016 | 07:04 EDT
Credit Suisse analyst Alethia Young downgraded PTC Therapeutics to Neutral and lowered its price target to $6 from $12 citing further uncertainty around the Eurozone DMD approval case. Following the company's release, Young believes that the approval timelines in EU at the best case are now longer than his original expectations though the drug does remain on the market and lowered his probability of success in EMA to 75% from $100.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
